Pure Global AI
NCT06062810Not yet recruiting

Pharmacogenomics IND EXEMPT SNP Clinical Study - Crizotinib and Single Nucleotide Polymorphisms

Explore the Relationship Between Single Nucleotide Polymorphisms and Crizotinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairPhase 2/3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-Small Cell Lung Cancer
Drug/Device/Intervention
Crizotinib - Usual
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Funder
Medicine Invention Design, Inc
Location
Rockville, United States of America
Timeline & enrollment
Phase
Phase 2/3
Start date
Oct 28, 2023
End date
Dec 28, 2024
Enrollment
600 participants
Primary outcome

Measure and Report Crizotinib oncology drug target ALK SNP Genotypes which are effectiveness-associated.,Measure and Report Crizotinib oncology drug target CYP4503A SNP Genotypes which are risk associated.

Summary

Explore the relationship between drug target ALK gene single nucleotide polymorphisms and
 XALKORI - Crizotinib therapeutic-effects in patients with non-small cell lung cancer, based
 on Oxford precisely sequencing drug targets' genes.
 
 Explore the relationship between drug target CYP4503A gene single nucleotide polymorphisms
 and XALKORI - Crizotinib side-effects in patients with non-small cell lung cancer, based on
 Oxford precisely sequencing drug targets' genes.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06062810
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06062810 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair and is currently Not yet recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.